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  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	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  our	  scienGfic	  inheritance,	  
through	  textbook	  histories	  of	  geneGcs	  and	  Thomas	  Kuhn's	  legacy	  
hMp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
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  by	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  W.	  F.	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  Weldon's	  Theory	  of	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Penetrance	  and	  Expressivity	  
•  We	  do	  not	  really	  know	  the	  penetrance	  or	  
expressivity	  of	  	  preMy	  much	  ALL	  mutaGons	  in	  
humans,	  as	  we	  have	  not	  systemaGcally	  
sequenced	  or	  karyotyped	  any	  geneGc	  alteraGon	  
in	  MILLIONS	  of	  well-­‐phenotyped	  people.	  
•  Do	  single	  mutaGons	  drive	  outcome	  
predominately,	  or	  are	  the	  results	  modified	  
substanGally	  by	  other	  mutaGons	  and/or	  
environment?	  	  Is	  there	  really	  such	  a	  thing	  as	  
geneGc	  determinism	  for	  MANY	  mutaGons?	  
Ogden	  Syndrome	  	  
The	  mutaGon	  is	  necessary,	  but	  we	  do	  not	  know	  if	  it	  is	  sufficient	  to	  cause	  this	  
phenotype	  in	  ANY	  geneGc	  background.	  It	  simply	  “contributes	  to”	  the	  phenotype.	  

	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
New	  Syndrome	  with	  Dysmorphology,	  Mental	  	  
RetardaGon,	  “AuGsm”,	  “ADHD”	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	   	   	   	  7	  years	  old 	   	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old 	   	   	   	  	  	  9	  years	  old 	  	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneGc	  tests	  negaGve,	  including	  
negaGve	  for	  Fragile	  X	  and	  many	  candidate	  genes.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  
normal.	  
•  Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics,	  
obtained	  data	  in	  June	  of	  this	  year,	  i.e.	  version	  2.0	  
CG	  pipeline.	  
22,174	  
272	  
56	  
7	  
6	  
5	  
3	  
SIFT	  classificaGon	  
Variant	  classificaGon	  
VAAST	  score	  
Chromosome	   PosiGon	   Reference	   Coding?	   SIFT	  Score	   Score	  <=	  0.05	   Ref/Alt	  Alleles	  
X	   47307978	   G	   YES	   0.649999976	   0	   G/T	  
X	   63444792	   C	   YES	   0	   1	   C/A	  
X	   70621541	   T	   YES	   0.009999999776	   1	   T/C	  
Variant	   Reference	   Alternate	   ClassificaGon	   Gene	  1	   Transcript	  1	   Exon	  1	   HGVS	  Coding	  1	   HGVS	  Protein	  1	  
X:47307978-­‐SNV	   G	   T	   Nonsyn	  SNV	   ZNF41	   NM_007130	   5	  c.1191C>A	   p.Asp397Glu	  
X:63444792-­‐SNV	   C	   A	   Nonsyn	  SNV	   ASB12	   NM_130388	   2	  c.739G>T	   p.Gly247Cys	  
X:70621541-­‐SNV	   T	   C	   Nonsyn	  SNV	   TAF1	   NM_004606	   25	  c.4010T>C	   p.Ile1337Thr	  
RANK	   Gene	   p-­‐value	   p-­‐value-­‐ci	   Score	   Variants	  
1	   ASB12	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   38.63056297	   chrX:63444792;38.63;C-­‐>A;G-­‐>C;0,3	  
2	   TAF1	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   34.51696816	   chrX:70621541;34.52;T-­‐>C;I-­‐>T;0,3	  
3	   ZNF41	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   32.83011803	   chrX:47307978;32.83;G-­‐>T;D-­‐>E;0,3	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
Address for correspondence and reprints: Dr. Vera Kalscheuer,Max-
Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195Berlin,
Germany. E-mail: kalscheu@molgen.mpg.de
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
Am. J. Hum. Gen t. 73:1341–1354, 2003
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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K10012-­‐10079	  
UNAFFECTED.	  
SNV	  A	  
SNV	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No	  skewing	  
K10012-­‐10083	  
Het	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Het	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Sanger	  valida5on:	  	  ASB12	  and	  ZNF41	  muta5ons	  
The	  mutaGon	  in	  ZNF41	  may	  NOT	  be	  necessary,	  and	  it	  is	  certainly	  
NOT	  sufficient	  to	  cause	  the	  phenotype.	  
So,	  of	  course	  we	  need	  baseline	  whole	  
genome	  sequencing	  on	  everyone	  to	  at	  
least	  understand	  the	  DNA	  geneGc	  
background	  in	  each	  pedigree	  or	  clan.	  
	  
Ancestry	  MaMers!	  
How	  do	  we	  get	  to	  “whole”	  genome	  
sequencing	  for	  everyone?	  
•  ~$3000	  for	  30x	  whole	  genome	  as	  part	  of	  Illumina	  
Genome	  Network	  on	  a	  research	  basis	  only,	  but	  ~$9,500	  
for	  whole	  genome	  performed	  in	  a	  CLIA	  lab	  at	  Illumina.	  
•  The	  price	  point	  of	  $5,000	  that	  was	  given	  for	  the	  
Illumina	  Understand	  Your	  Genome	  Symposium	  was	  
basically	  below	  cost	  (52	  genomes	  delivered).	  
•  And	  it	  is	  my	  understanding	  that	  many	  projects	  don’t	  
want	  to	  pay	  even	  $5K	  for	  a	  whole	  genome	  in	  the	  CLIA	  
lab	  at	  Illumina.	  
Method
Accurate and comprehensive sequencing
of personal genomes
Subramanian S. Ajay,1 Stephen C.J. Parker,1 Hatice Ozel Abaan,1
Karin V. Fuentes Fajardo,2 and Elliott H. Margulies1,3,4
1Genome Informatics Section, Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health,
Bethesda, Maryland 20892, USA; 2Undiagnosed Diseases Program, Office of the Clinical Director, National Human Genome Research
Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
As whole-genome sequencing becomes commoditized and we begin to sequence and analyze personal genomes for clinical
and diagnostic purposes, it is necessary to understand what constitutes a complete sequencing experiment for determining
genotypes and detecting single-nucleotide variants. Here, we show that the current recommendation of ~30@ coverage is
not adequate to produce genotype calls across a large fraction of the genome with acceptably low error rates. Our results
are based on analyses of a clinical sample sequenced on two related Illumina platforms, GAIIx and HiSeq 2000, to a very
high depth (126@). We used these data to establish genotype-calling filters that dramatically increase accuracy. We also
empirically determined how the callable portion of the genome varies as a function of the amount of sequence data used.
These results help provide a ‘‘sequencing guide’’ for future whole-genome sequencing decisions and metrics by which
coverage statistics should be reported.
[Supplemental material is available for this article.]
Whole-genome sequencing and analysis is becoming part of a
translational research toolkit (Lupski et al. 2010; Sobreira et al.
2010) to investigate small-scale changes such as single-nucleotide
variants (SNVs) and indels (Bentley et al. 2008; Wang et al. 2008;
Kim et al. 2009; McKernan et al. 2009; Fujimoto et al. 2010; Lee
et al. 2010; Pleasance et al. 2010) in addition to large-scale events
such as chromosomal rearrangements (Campbell et al. 2008;
Chen et al. 2008) and copy-number variation (Chiang et al. 2009;
Park et al. 2010). For both basic genome biology and clinical
diagnostics, the trade-offs of data quality and quantity will de-
termine what constitutes a ‘‘comprehensive and accurate’’ whole-
genome analysis, especially for detecting SNVs. As whole-genome
sequencing becomes commoditized, it will be important to deter-
mine quantitative metrics to assess and describe the comprehen-
siveness of an individual’s genome sequence. No such standards
currently exist.
For several reasons (sample handling, platform biases, run-
to-run variation, etc.), random generation of sequencing reads
does not always represent every region in the genome uniformly.
It is therefore necessary to understand what proportion of the
whole genome can be accurately ascertained, given a certain amount
and type of input data and a specified reference sequence. The
1000 Genomes Project (which aims to accurately assess genetic
variation within the human population) refers to this concept as
the ‘‘accessible’’ portion of the reference genome (1000 Genomes
Project Consortium 2010). While population-scale sequencing
focuses on low-coverage pooled data sets, here we focus on require-
ments for highly accurate SNV calls from an individual’s genome,
a question that is extremely important as whole-genome se-
quencing and analysis of individual genomes transitions from
primarily research-based projects to being used for clinical and
diagnostic applications. Additionally, we seek to understand the
relationship between the amount of sequence data generated and
the resulting proportion of the genome where confident geno-
types can be derived—we refer to this as the ‘‘callable’’ portion,
a term that is roughly equivalent to the 1000 Genomes Project’s
‘‘accessible’’ portion. Using these sequencing metrics and geno-
type-calling filters will help obviate the need for costly and time-
consuming validation efforts. Currently, no empirically derived
data sets exist for determining howmuch sequence data is needed
to enable accurate detection of SNVs.
To address this issue, we sequenced a blood sample from a
male individual with an undiagnosed clinical condition on two
related platforms—Illumina’s GAIIx and HiSeq 2000—to a total of
359 Gb (equivalent to;1263 average sequenced depth). Here we
focus on the technical aspects of analyzing these data generated
as part of the expanded whole-genome sequencing efforts of the
National Institutes of Health (NIH) Undiagnosed Diseases Pro-
gram (UDP).We leveraged the ultra-deep coverage of this genome
to identify sources of incorrect genotype calls and developed ap-
proaches to mitigate these inaccuracies. We generated incremen-
tal data sets of the deep-sequenced genome to answer the fol-
lowing important questions: Given a specific amount of sequence
data, what fraction of the genome is callable? and how many
SNVs are detected? Ultimately, we seek to understand how much
sequence data is needed for adequate representation of the whole
genome for genotype calling and to develop standards by which
all whole-genome data sets can be evaluated with respect to
comprehensiveness.
Answers to these questions will help us make more informed
decisions for designing whole-genome sequencing experiments to
study genome biology and for clinical analyses, specifically in light
of accurately detecting variants that directly modify phenotypes
and cause disease.
3Present address: IlluminaCambridge Ltd., ChesterfordResearchPark,
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Accurate whole-genome sequencing and
haplotyping from 10 to 20 human cells
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Recent advances in whole-genome sequencing have brought the vision of personal genomics and genomic medicine
closer to reality. However, currentmethods lack clinical accuracy and the ability to describe the context (haplotypes) in
which genome variants co-occur in a cost-effective manner. Here we describe a low-cost DNA sequencing and
haplotyping process, long fragment read (LFR) technology, which is similar to sequencing long single DNA molecules
without cloning or separation of metaphase chromosomes. In this study, ten LFR libraries were made using only
100 picograms of human DNA per sample. Up to 97% of the heterozygous single nucleotide variants were assembled
into long haplotype contigs. Removal of false positive single nucleotide variants not phased by multiple LFR haplotypes
resulted in a final genome error rate of 1 in 10megabases. Cost-effective and accurate genome sequencing and
haplotyping from 10–20 human cells, as demonstrated here, will enable comprehensive genetic studies and diverse
clinical applications.
The extraordinary advancements made in DNA sequencing tech-
nologies over the past few years have led to the elucidation of
,10,000 (refs 1–13) individual human genomes (303 or greater base
coverage) from different ethnicities and using different tech-
nologies2–13 and at a fraction of the cost10 of sequencing the original
human reference genome14,15. Although this is a monumental
achievement, the vast majority of these genomes have excluded a very
important element of human genetics. Individual human genomes are
diploid in nature, with half of the homologous chromosomes being
derived from each parent. The context in which variations occur on
each individual chromosome can have profound effects on the
expression and regulation of genes and other transcribed regions of
the genome16. Furthermore, determining whether two potentially
detrimental mutations occur within one or both alleles of a gene is
of paramount clinical importance.
Almost all recent human genome sequencing has been performed
on short read length (,200 base pairs (bp)), highly parallelized
systems starting with hundreds of nanograms of DNA. These tech-
nologies are excellent at generating large volumes of data quickly and
economically. Unfortunately, short reads, often paired with small
mate-gap sizes (500 bases–10 kilobases (kb)), eliminate most single
nucleotide polymorphism (SNP) phase information beyond a few
kilobases8. Population-based genotype data has been used to success-
fully assemble short-read data into long haplotype blocks3, but these
methods suffer from higher error rates and have difficulty phasing
rare variants17. Although using pedigree information18 or combining
it with population data provides further phasing power, no combina-
tion of these methods is able to resolve de novo mutations17.
At present, four personal genomes—J. Craig Venter19, a Gujarati
Indian (HapMap sample NA20847)11, and two Europeans (Max
Planck One13 and HapMap Sample NA12878 (ref. 20))—have been
sequenced and assembled as diploid. All have involved cloning long
DNA fragments in a process similar to that used for the construction
of the human reference genome14,15. Although these processes
generate long-phased contigs (N50 values (50% of the covered bases
are found within contigs longer than this number) of 350 kb19,
386 kb11 and 1megabase (Mb)13, and full-chromosome haplotypes
in combination with parental genotypes20) they require a large
amount of initial DNA, extensive library processing, and are currently
too expensive11 to use in a routine clinical environment. Furthermore,
several reports have recently demonstrated whole chromosome
haplotyping through direct isolation of metaphase chromosomes21–24.
These methods have yet to be used for whole-genome sequencing and
require preparation and isolation of whole metaphase chromosomes,
which can be challenging for some clinical samples. Here we introduce
long fragment read (LFR) technology, a process that enables genome
sequencing and haplotyping at a clinically relevant cost, quality and
scale.
LFR technology
The LFR approach can generate long-range phased variants because it
is conceptually similar to single-molecule sequencing of fragments
10–1,000 kb25 in length. This is achieved by the stochastic separation
of corresponding long parental DNA fragments into physically
distinct pools followed by subsequent fragmentation to generate
shorter sequencing templates (Fig. 1). The same principles are used
in aliquoting fosmid clones11,13. As the fraction of the genome in
each pool decreases to less than a haploid genome, the statistical
likelihood of having a corresponding fragment from both parental
chromosomes in the same pool markedly diminishes25. For example,
0.1 genome equivalents (300Mb) per well yields an approximately
10% chance that two fragments will overlap, and a 50% chance that
1Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, California 94043, USA. 2Department of Genetics, Harvard Medical School, Cambridge, Massachusetts 02115, USA. 3Program in
Bioinformatics, Boston University, Boston, Massachusetts 02215, USA. 4Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, Cambridge, Massachusetts 02115, USA. {Present
addresses: Aria Diagnostics, 5945 Optical Court, San Jose, California 95138, USA (A.B.S.); Halo Genomics, Dag Hammarskjolds vag 54A, 751 83 Uppsala, Sweden (F.D.).
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Recent advances in whole-genome sequencing have brought the vision of personal genomics and genomic medicine
closer to reality. However, currentmethods lack clinical accuracy and the ability to describe the context (haplotypes) in
which genome variants co-occur in a cost-effective manner. Here we describe a low-cost DNA sequencing and
haplotyping process, long fragment read (LFR) technology, which is similar to sequencing long single DNA molecules
without cloning or separation of metaphase chromosomes. In this study, ten LFR libraries were made using only
100 picograms of human DNA per sample. Up to 97% of the heterozygous single nucleotide variants were assembled
into long haplotype contigs. Removal of false positive single nucleotide variants not phased by multiple LFR haplotypes
resulted in a final genome error rate of 1 in 10megabases. Cost-effective and accurate genome sequencing and
haplotyping from 10–20 human cells, as demonstrated here, will enable comprehensive genetic studies and diverse
clinical applications.
The extraordinary advancements made in DNA sequencing tech-
nologies over the past few years have led to the elucidation of
,10,000 (refs 1–13) individual human genomes (303 or greater base
coverage) from different ethnicities and using different tech-
nologies2–13 and at a fraction of the cost10 of sequencing the original
human reference genome14,15. Although this is a monumental
achievement, the vast majority of these genomes have excluded a very
important element of human genetics. Individual human genomes are
diploid in nature, with half of the homologous chromosomes being
derived from each parent. The context in which variations occur on
each individual chromosome can have profound effects on the
expression and regulation of genes and other transcribed regions of
the genome16. Furthermore, determining whether two potentially
detrimental mutations occur within one or both alleles of a gene is
of paramount clinical importance.
Almost all recent human genome sequencing has been performed
on short read length (,200 base pairs (bp)), highly parallelized
systems starting with hundreds of nanograms of DNA. These tech-
nologies are excellent at generating large volumes of data quickly and
economically. Unfortunately, short reads, often paired with small
mate-gap sizes (500 bases–10 kilobases (kb)), eliminate most single
nucleotide polymorphism (SNP) phase information beyond a few
kilobases8. Population-based genotype data has been used to success-
fully assemble short-read data into long haplotype blocks3, but these
methods suffer from higher error rates and have difficulty phasing
rare variants17. Although using pedigree information18 or combining
it with population data provides further phasing power, no combina-
tion of these methods is able to resolve de novo mutations17.
At present, four personal genomes—J. Craig Venter19, a Gujarati
Indian (HapMap sample NA20847)11, and two Europeans (Max
Planck One13 and HapMap Sample NA12878 (ref. 20))—have been
sequenced and assembled as diploid. All have involved cloning long
DNA fragments in a process similar to that used for the construction
of the human reference genome14,15. Although these processes
generate long-phased contigs (N50 values (50% of the covered bases
are found within contigs longer than this number) of 350 kb19,
386 kb11 and 1megabase (Mb)13, and full-chromosome haplotypes
in combination with parental genotypes20) they require a large
amount of initial DNA, extensive library processing, and are currently
too expensive11 to use in a routine clinical environment. Furthermore,
several reports have recently demonstrated whole chromosome
haplotyping through direct isolation of metaphase chromosomes21–24.
These methods have yet to be used for whole-genome sequencing and
require preparation and isolation of whole metaphase chromosomes,
which can be challenging for some clinical samples. Here we introduce
long fragment read (LFR) technology, a process that enables genome
sequencing and haplotyping at a clinically relevant cost, quality and
scale.
LFR technology
The LFR approach can generate long-range phased variants because it
is conceptually similar to single-molecule sequencing of fragments
10–1,000 kb25 in length. This is achieved by the stochastic separation
of corresponding long parental DNA fragments into physically
distinct pools followed by subsequent fragmentation to generate
shorter sequencing templates (Fig. 1). The same principles are used
in aliquoting fosmid clones11,13. As the fraction of the genome in
each pool decreases to less than a haploid genome, the statistical
likelihood of having a corresponding fragment from both parental
chromosomes in the same pool markedly diminishes25. For example,
0.1 genome equivalents (300Mb) per well yields an approximately
10% chance that two fragments will overlap, and a 50% chance that
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“SubstanGal	  error	  rates	  (1	  single	  nucleoGde	  variants	  (SNV)	  in	  100–1,000	  called	  
kilobases)	  a e	  a	  c mmon	   Mribute	  of	  all	  current	  mas ively	  
parallelized	  sequencing	  t c nologies.	  These	  rates	  are	  proba ly	  too	  high	  for	  
diagnosGc	  use	  and	  complicate	  many	  studies	  searching	  for	  
new	  mutaGons.”	  
	  
Much	  Higher	  Accuracy	  with	  LFR	  data	  
“To	  test	  LFR	  reproducibility	  we	  compared	  haplotype	  data	  between	  the	  two	  
NA19240	  replic te	  librari .	  In	  gen ral,	  the	  libraries	  w r 	  v ry	  concordant,	  with	  
nly	  64	  differe ces	  per	  library	  in	  2.2	  million	  heterozygou 	  SNPs	  pha ed	   y	  both	  
libraries	  or	  1	  of	  this	  error	  type	  in	  44	  Mb.”	  
	  
Toward	  more	  comprehensive	  
“personal	  genomes”	  
•  Can	  we	  reliably	  detect	  a	  comprehensive,	  and	  
accurate,	  set	  of	  variants	  using	  more	  than	  one	  
pipeline,	  or	  even	  more	  than	  one	  sequencing	  
playorm?	  
•  How	  much	  data	  is	  enough,	  and	  how	  reliable	  
and	  reproducible	  are	  variant	  calls?	  
Depth	  of	  Coverage	  in	  15	  exomes	  >	  20	  
reads	  per	  bp	  in	  target	  region	  
>=1 >=10 >=20
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Pipelines	  Used	  on	  Same	  Set	  of	  Seq	  Data	  by	  Different	  
Analysts,	  using	  Hg19	  Reference	  Genome	  
1)  BWA	  -­‐	  GATK	  (version	  1.5)	  with	  recommended	  parameters	  	  (GATK	  IndelRealigner,	  
base	  quality	  scores	  were	  re-­‐calibrated	  by	  GATK	  Table	  RecalibraGon	  tool.	  
Genotypes	  called	  by	  GATK	  UnifiedGenotyper.	  For	  SNVs	  and	  indels.	  
	  
2)  BWA	  -­‐	  SamTools	  version	  0.1.18	  to	  generate	  genotype	  calls	  	  -­‐-­‐	  The	  “mpileup”	  
command	  in	  SamTools	  was	  used	  for	  idenGfy	  SNVs	  and	  indels.	  
	  
3)  SOAP-­‐Align	  –	  SOAPsnp	  for	  SNVs–	  and	  BWA-­‐SOAPindel	  (adopts	  local	  assembly	  
based	  on	  an	  extended	  de	  Bruijn	  graph)	  for	  indels.	  
	  
4)  GNUMAP-­‐SNP	  (probabilisGc	  Pair-­‐Hidden	  Markov	  which	  effecGvely	  accounts	  for	  
uncertainty	  in	  the	  read	  calls	  as	  well	  as	  read	  mapping	  in	  an	  unbiased	  fashion),	  for	  
SNVs	  only.	  
	  
5)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  –	  SNVer	  ,	  for	  SNVs	  
only	  
Known	   Novel	  
All	  
•  Pipeline	  concordance	  is	  much	  beMer	  for	  
known	  and	  common	  human	  variaGons	  (in	  
dbSNP135).	  
•  How	  reliable	  are	  variants	  that	  are	  uniquely	  
called	  by	  individual	  pipelines?	  
•  Are	  some	  pipelines	  beMer	  at	  detecGng	  rare,	  or	  
novel	  variants	  than	  others?	  
Total	  mean	  overlap,	  plus	  or	  minus	  one	  standard	  devia5on,	  observed	  between	  three	  
indel	  calling	  pipelines:	  GATK,	  SOAP-­‐indel,	  and	  SAMTools.	  	  a)	  Mean	  overlap	  when	  indel	  
posiGon	  was	  the	  only	  necessary	  agreement	  criterion.	  b)	  Mean	  overlap	  when	  indel	  
posiGon,	  base	  length	  and	  base	  composiGon	  were	  the	  necessary	  agreement	  criteria.	  	  	  
Indels-­‐	  Overlap	  by	  Base	  	  
PosiGon	  only	  
Indels-­‐	  Overlap	  by	  Base	  	  
PosiGon,	  Length	  and	  ComposiGon	  
INDELS	  
Illumina	  SNVs	  
CG	  SNVs	  
Illumina	  indels	  
CG	  Indels	  
1698	  4364	  
2613	  
What	  is	  the	  “True”	  Personal	  Genome?	  
35653	   19407	  17322	  
2666	  
18331	   2085	  
915	  
50.5%	   32.2%	   17.3%	  
48.6%	   45.9%	   5.5%	  
Cross	  validaGon	  using	  orthogonal	  
sequencing	  technology	  
	  (Complete	  Genomics)	  
Known	   Novel	  
All	  
Cross	  validaGon	  using	  orthogonal	  
sequencing	  tech	  (Complete	  Genomics)	  
•  Reveals	  higher	  validaGon	  rate	  of	  unique-­‐to-­‐
pipeline	  variants,	  as	  well	  as	  uniquely	  
discovered	  novel	  variants,	  for	  the	  variants	  
called	  by	  BWA-­‐GATK,	  in	  comparison	  to	  the	  
other	  4	  pipelines	  (including	  SOAP).	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Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked.	  
Clinical	  Validity	  with	  Worldwide	  
Human	  GeneGc	  VariaGon	  “database”?	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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. !at said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing efforts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
Conclusions	  
•  Ancestry,	  i.e.	  geneGc	  background,	  maMers!	  
•  We	  need	  to	  sequence	  whole	  genomes	  of	  large	  
pedigrees,	  and	  then	  construct	  super-­‐family	  
structures.	  
•  CollecGvely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  
parGcipants	  and	  consumers.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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